1. Academic Validation
  2. Interstitial lung disease

Interstitial lung disease

  • Eur Respir Rev. 2014 Mar 1;23(131):40-54. doi: 10.1183/09059180.00009113.
Katerina M Antoniou 1 George A Margaritopoulos Sara Tomassetti Francesco Bonella Ulrich Costabel Venerino Poletti
Affiliations

Affiliation

  • 1 Dept of Thoracic Medicine and Laboratory of Cellular and Molecular Pneumonology, Medical School, University of Crete, Crete, Greece. 2 Pulmonary Unit, GB Morgagni Hospital, Forlì, Italy. 3 Dept of Pneumology and Allergy, Ruhrlandklinik, University Hospital, University of Duisburg Essen, Essen, Germany.
Abstract

Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the publication of the new classification of idiopathic interstitial pneumonias, according to which there are three groups: major, rare and unclassified. The novelty of the new classification comes from the fact that difficult to classify entities can be treated according to the disease behaviour classification. Idiopathic pulmonary fibrosis is the most lethal amongst the interstitial lung diseases and presents high heterogeneity in clinical behaviour. A number of biomarkers have been proposed in order to predict the course of the disease and group patients with the same characteristics in clinical trials. Early diagnosis and disease stratification is also important in the field of Other interstitial lung diseases.

Figures